A New Piece in the 3D Jigsaw of Malaria Parasite  by Jaskolski, Mariusz
Structure
PreviewsA New Piece in the 3D Jigsaw of Malaria ParasiteMariusz Jaskolski1,*
1Department of Crystallography, Faculty of Chemistry, A. Mickiewicz University and Center for Biocrystallographic Research,
Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland
*Correspondence: mariuszj@amu.edu.pl
DOI 10.1016/j.str.2011.06.005
The structural insights presented by Hansen et al. in this issue of Structure on how a key malaria parasite
protease is blocked by its inhibitor may provide a flicker of hope in the desperate struggle to develop drugs
against one of the most severe health problems.Despite all the recent progress in dissect-
ing their genetic makeup and intricate life
cycles, Plasmodium falciparum and re-
lated protozoan parasites still have the
upper hand, claiming nearly one million
lives a year among the close to onequarter
of a billion malaria victims. Some of the
infamous relatives ofP. falciparum include
Trypanosoma cruzi (which causes Cha-
gas’ disease in humans) or P. berghei
(which afflicts other mammals). Part of
the exquisite systemusedby theparasites
to control their amazing life cycle involves
the conceptually simple system of a
balance that is created between cysteine
proteases (CPs) and their inhibitors (ICPs).
CP activity is essential not only for
Plasmodium development in the vector
mosquito but also for the intracellular
stages of the parasite life cycle in the
human host. Within liver and erythrocyte
cells, CPs activate other enzymes, facili-
tate parasite bursts from the cells, and
initiate an unusual nonapoptotic host-cell
death. For example, falcipain-2 (FP-2),
a ubiquitous CP of intra-erythrocyte
Plasmodium parasites, acts as hemoglo-
binase in malaria, destroying red bloodFigure 1. Structural Determinants of ICP-C-Fal
The topological layout of ICP-C (A) is generally simila
(yellow) of the enzyme, shown with gray surface in (B
the inhibitory epitope of ICP-C consists of four rather
loop L3, together with prominent extensions in the loocells. There is also possible interference
with the functioning of human CPs that
belong to the same or similar class as
falcipain and participate in the defense
against the pathogen, as they take part in
antigen processing and presentation (in
the case of cathepsin L), or play a role in
programmed cell death (such as cas-
pases). All this requires a fine-tuned
temporal and site-specific synchroniza-
tion of CPs, which is achieved through
the activity of ICPs. For instance, ICPs
block a premature host cell apoptosis
before the nascent parasites egress.
For a number of years, our knowledge
regarding CP-ICP equilibria appeared
complete, with the ubiquitous protein
inhibitors called cystatins playing a prom-
inent role in these processes. It was there-
fore an unexpected finding a couple of
years ago when a protozoan CP inhibitor
with size and properties similar to those
of a cystatin turned out to have a com-
pletely different b-barrel-type fold, with
prominent loops L4, L2, and L6 acting as
the enzyme-binding epitope (Salmon
et al., 2006; Ljunggren et al., 2007). Even
more curiously, the new inhibitor—calledcipain Interactions
r to that of chagasin, with three major loops (L2, L4, a
). However, in contrast with chagasin (and indeed a la
than three loops, with L0 acting as an auxiliary prong.
p regions.
Structure 19, July 13, 2011chagasin because it was found in theCha-
gas’ disease-causing T. cruzi —despite
its novel fold, used the same three-prong
plugging of the target enzyme character-
istic of cystatins. Also in complex with
FP-2, chagasin used the L4-L2-L6
epitope for inhibition (Wang et al., 2007).
This complex between a protozoan
enzyme and a protozoan inhibitor was
thought at first to be a highly realistic
model for the condition encountered in
the native Plasmodium system. Logical
enough? Wrong!
The first surprise came from the obser-
vation that the Plasmodium ICPs have
sequences that are much longer than
chagasin. We now know that the in-
hibitory function resides in a C-terminal
domain, termed ICP-C, which is preceded
by a nonhomologous poorly conserved
N-terminal portion. But even in the ICP-C
domain, sequence similarity to chagasin
is low, and the domain is much larger
than chagasin. The crystallographic study
of ICP-C from P. berghei presented in this
issue of Structure by Hansen et al. (2011)
demonstrates that the insertions are
mostly found in loop regions. This finding,nd L6) playing a key role in plugging the active site
rge class of CP inhibitors that includes cystatins),
In addition, there is a contribution from a backside
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Previewsnot unexpected in general, is odd for a
chagasin-like inhibitor, in which the loops
are the business center of the molecule.
Perhaps the most exciting, however, is
the discovery that, in complex with FP-2
from P. falciparum, the P. berghei ICP-C
uses not a three-prong, but a four-prong
epitope. The fourth loop, L0, is not aligned
with L4-L2-L6 in a wedge-like fashion, but
acts as an accessory element docked
away from theactive site groove (Figure 1).
This finding,which could not be gleaned
from complex structures of suboptimally
matched CP–ICP pairs, provides at last
a clear perspective for the structural902 Structure 19, July 13, 2011 ª2011 Elsevidesign of selective high-affinity inhibitors
of Plasmodium cysteine proteases. In this
regard, malaria drugs that target falcipain
by exploiting the L0 accessory inhibitor
binding site might achieve higher effi-
ciency while avoiding the risk of crippling
similar human enzymes, e.g., cathepsin
L. This is why the structure presented by
Hansen et al. (2011) is so important for
a potential rational design of antimalarials.REFERENCES
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New NMR structures of complexes between double-strand RNA binding domains and their RNA hairpin
substrates reported by Wang et al. in this issue of Structure reveal striking adaptations in both the protein
recognition element and in the RNA.RNA molecules play amazingly diverse
roles in biology. They display these bio-
logical functions because of the diversity
of the three-dimensional structures they
adopt. Most RNA transcripts undergo
many maturation processes (i.e., precise
cleavages, deamination during editing,
or nucleotidemodifications such asmeth-
ylation). Furthermore, because RNA heli-
ces are so stable and form rapidly, tran-
scripts may adopt either transient states
or fall into kinetic traps. Helicases or cha-
perone proteins acting on such structures
are therefore necessary. However, RNA
molecules rarely exert their biological
functions alone. In the vast majority of
cases, RNA molecules act in complex
with either one or several proteins after
they form ribonucleoparticles or RNPs.
The number of different RNPs is huge
and probably innumerable, owing to the
large diversity of possible assemblies
with various components. These RNPs
are generally catalytic (e.g., ribonuclease
P, telomerase, H/ACA RNP pseudouridy-lase), or they participate in a catalytic
process such as the snurps in splicing or
the RISC complexes in microRNA pro-
cessing. Either way, a precise molecular
recognition between RNA elements and
protein residues or protein scaffolds is
crucial.
Crystallographic and NMR methods
yield the most accurate structural models
for understanding this molecular recogni-
tion. Although the number of crystal struc-
tures of RNA and of RNA complexes is
just a tiny fraction of the available protein
structures, this number is steadily in-
creasing, albeit at a slow pace. In this
issue, Wang et al. (2011) describe the
NMR structures of a double-strand RNA
binding domain bound to two different
hairpins. The understanding of the under-
lying molecular recognition is particularly
important in this instance, as the double-
strand RNA binding domain is part of the
enzyme Rnt1p that belongs to the RNase
III family. Rnt1p plays essential roles in
the maturation of RNA transcripts inbudding yeasts. The RNase III family
includes such famous enzymes as Drosha
and Dicer, which process microRNAs
(MacRae and Doudna, 2007).
RNA helices display less variation in
pitch and rise than DNA helices, however
the size of the RNA grooves is significantly
different from DNA. In DNA, there are two
grooves of equal depth but of different
lengths, giving rise to the major and minor
grooves. In RNA, the major groove has
become narrow and deep with the minor
groove becoming shallow and large.
These geometric differences are recog-
nized globally and in a sequence-
independent manner by double-strand
binding protein domains, in particular
through binding to phosphate groups
and often, but not always, the 20 hydroxyl
group of the ribose (Fierro-Monti and
Mathews, 2000; Ryter and Schultz,
1998). Some double-strand binding do-
mains are able to measure the length of
the RNA helix; this is achieved through
protein-protein interactions that lock
